Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial  

Oleh:

Engman, M. ; Granberg, S. ; Williams, A.R.W. ; Meng, C.X.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Human Reproduction vol. 24 no. 08 (Aug. 2009), page 1870-1879.
Topik: mifepristone/leiomyoma/bleeding/endometrial morphology

Ketersediaan

Perpustakaan FK Nomor Panggil: H07.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

BACKGROUND: Uterine leiomyomas are widely prevalent and frequently cause menorrhagia. The major therapeutic option today is hysterectomy. Medical options are of highest interest. METHODS: A total of 30 women with uterine leiomyomas scheduled for surgical intervention were randomized to receive either 50 mg mifepristone or placebo every other day during 3 months prior to surgery. Uterine blood flow and leiomyoma volume were evaluated once a month until surgery. Endometrial biopsies were obtained prior to and at end of treatment. Relevant biochemistry, symptoms and bleeding were recorded. Primary outcome was reduction in uterine leiomyoma size. RESULTS: There was a significant percentual decrease (P = 0.021) in the total leiomyoma volume in the mifepristone-treated group, –28 (–48, –8) % (mean ± 0, 95 confidence interval), compared with the control group values 6 (–13, 25) %. Mifepristone treatment significantly reduced the bleeding days (P = 0.001) and increased serum haemoglobin values (P = 0.046). Serum cortisol levels remained unchanged, while a mild increase in serum androgens was noted. Endometrial biopsies showed no premalignant changes or changes in mitotic indices. CONCLUSION: Mifepristone may offer an effective treatment option for women with uterine leiomyoma and the associated pronounced uterovaginal bleeding.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali